| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna.
Looking at options history for Moderna (NASDAQ:MRNA) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 18% of the investors opened trades with bullish expectations and 63% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $259,763 and 7, calls, for a total amount of $365,412.
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $69.0 to $160.0 for Moderna over the recent three months.
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Moderna's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Moderna's significant trades, within a strike price range of $69.0 to $160.0, over the past month.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MRNA | PUT | SWEEP | BULLISH | 03/21/25 | $11.1 | $11.0 | $11.0 | $70.00 | $144.1K | 2.5K | 149 |
| MRNA | CALL | SWEEP | NEUTRAL | 09/06/24 | $1.5 | $1.5 | $1.49 | $75.00 | $81.5K | 678 | 1.1K |
| MRNA | PUT | TRADE | BEARISH | 10/11/24 | $3.8 | $3.55 | $3.8 | $69.00 | $61.5K | 3 | 0 |
| MRNA | CALL | TRADE | BULLISH | 11/15/24 | $4.4 | $4.35 | $4.4 | $85.00 | $55.4K | 304 | 126 |
| MRNA | CALL | TRADE | BEARISH | 09/27/24 | $6.65 | $6.2 | $6.3 | $69.00 | $52.9K | 1 | 84 |
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Following our analysis of the options activities associated with Moderna, we pivot to a closer look at the company's own performance.
In the last month, 3 experts released ratings on this stock with an average target price of $83.33333333333333.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with Benzinga Pro for real-time alerts.
Posted In: MRNA
